Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Celgene's Otezla Sale Shows FTC Wants Merging Companies To Ditch Marketed, Not Pipeline, Products
Aug 30 2019
•
By
Brenda Sandburg
FTC Requirements for the Celgene/Bristol-Myers Squibb Merger Reflect its Policy Shift on asset divestment.
More from Compliance
More from Pink Sheet